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Prostaglandin D2 is known to be the major prostanoid
produced by allergen-activated mast cells, but its role
in the formation of allergic diseases is not well estab-
lished because of complexity of its receptor system
and lack of appropriate inhibitors. We have recently
identi®ed a new-type prostaglandin D2 receptor,
named CRTH2. Studies with normal subjects have
shown that CRTH2 appears to be selectively
expressed by T helper 2 cells but not T helper 1 cells
among circulating CD4+ lymphocytes. The exact
correlation between CRTH2 and T helper 2 cells in
various disease settings and the impact of CRTH2-
mediated prostaglandin D2 activities on various T
helper 2 responses in vivo still remain to be elucidated,
however. In this study, we investigated the correl-
ation between CRTH2 and T helper 2 cells among
circulating CD4+ lymphocytes in normal adults and
patients with atopic dermatitis, a T-helper-2-involv-
ing disease. The results showed that virtually all
CRTH2+CD4+ lymphocytes had a pure T helper 2
phenotype and formed not all but a large proportion
of circulating T helper 2 cells for both normal and
atopic dermatitis subjects. In chemotaxis assays, per-
ipheral blood CRTH2+CD4+ lymphocytes were sig-
ni®cantly attracted by prostaglandin D2 as well as by
a typical T-helper-2-attracting chemokine, thymus
and activation regulated chemokine, whereas they
showed little chemotactic migration toward typical
T-helper-1-attracting chemokines, macrophage
in¯ammatory protein 1b and interferon-g-inducible
protein 10. Furthermore, in atopic dermatitis
patients, a preferential increase of CRTH2+ cells was
noted within the disease-related cutaneous lympho-
cyte-associated antigen-positive, but not the cuta-
neous lymphocyte-associated antigen-negative, CD4+
lymphocyte compartment. Our results suggest the
involvement of the prostaglandin D2/CRTH2 system
in both normal and pathogenic T helper 2 responses.
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I
n response to antigen stimulation, some CD4+ T [T helper
(Th)] cells differentiate into two major effector Th cell
subsets, Th1 and Th2, which mediate different types of
protective or pathogenic immune responses by secreting
particular cytokines; in humans, Th1 cells mainly secrete
interferon g (IFN-g) whereas Th2 cells secrete interleukin-4 (IL-4),
IL-5, and IL-13 (Mosmann and Coffman, 1989; Romagnani, 1994;
Abbas et al, 1996). Recent studies have demonstrated that Th1 and
Th2 cells also differ from each other in their migratory property
into the in¯amed tissues, which is believed to contribute largely to
the development of polarized Th1- or Th2-type in¯ammation
(Austrup et al, 1997; Syrbe et al, 1999). In this context, in the last
few years, a large number of studies have examined the differential
expression of chemokine receptors between Th1 and Th2 cells. It
has been shown that CXC chemokine receptor 3 (CXCR3) and
CC chemokine receptor 5 (CCR5) are preferentially expressed on
Th1 cells (Bonecchi et al, 1998; Loetscher et al, 1998), whereas
CCR3, CCR4, and CCR8 are selectively associated with Th2 cells
(Sallusto et al, 1997, 1998a, b; Bonecchi et al, 1998; D'Ambrosio et
al, 1998; Imai et al, 1999). Although these studies have shed light on
the basic principles of the Th cell traf®cking, in vivo correlation of
these molecules with Th1 or Th2 cells remains to be established
(Syrbe et al, 1999; Sallusto et al, 2000; Kim et al, 2001).
CRTH2, a G protein-coupled receptor, is another surface
molecule associated with Th2 cells (Nagata et al, 1999a; Cosmi et al,
2000). Interestingly, CRTH2 is also expressed on three other
allergy-related cell types: eosinophils, basophils, and Th2-type
CD8+ T cells (Nagata et al, 1999b; Cosmi et al, 2000). Recent
studies from our laboratories have found that CRTH2 functions as
a new-type receptor for prostaglandin D2 (PGD2), a major
prostanoid of activated mast cells (Lewis et al, 1982), and that
CRTH2 induces chemotactic migration toward PGD2 in cultured
Th2 cells as well as in peripheral blood eosinophils and basophils
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(Hirai et al, 2001). These ®ndings suggest that the PGD2/CRTH2
system may play a role in the traf®cking of Th2 cells in a different
layer from the chemokine/chemokine receptor system. The precise
relationship between CRTH2 and Th2 cells in various disease
settings, however, and the impact of CRTH2-mediated PGD2
activities on various Th2 responses are still unclear.
Atopic dermatitis (AD) is a skin disease known to involve
enhanced Th2 responses (Reinhold et al, 1991). Recent studies
have shown an increment of not only Th2 but also Th1 and Th0
cells in the lesional skin of AD (Grewe et al, 1994, 1995, 1998;
Hamid et al, 1994, 1996; Thepen et al, 1996). Interestingly, the
expansion of Th2 cells, but not Th1 cells, in the skin appeared to be
well re¯ected in peripheral blood Th cells that express the skin-
homing receptor cutaneous lymphocyte-associated antigen (CLA)
(Berg et al, 1991; Santamaria Babi et al, 1995; Akdis et al, 1997;
Teraki et al, 2000). In this study, we demonstrate that CRTH2 is
frequently and selectively associated with Th2 cells among
circulating Th cells of patients with AD and that the number of
CRTH2+ cells in the skin-related CLA-positive Th cell compart-
ment correlates with the severity of AD. Our results suggest the
involvement of the PGD2/CRTH2 system in both normal and
pathogenic Th2 responses.
MATERIALS AND METHODS
Subject Peripheral blood samples were obtained from 33 consenting
healthy volunteers (mean age, 31.7 6 5.5 y) and 40 patients with AD
(mean age, 30.8 6 11.6 y), who were diagnosed on the basis of the
criteria of Hani®n and Rajka (1980). The AD patients were categorized
into three groups (®ve mild, 18 moderate, and 17 severe AD patients)
according to the classi®cation system of severity of AD used by Rajka
and Langeland (1989).
Reagents Fluorescein isothiocyanate (FITC) labeled monoclonal
antibodies (mAbs) to CD3 (Leu-4), IFN-g (25723.11), and CLA
(HECA-452), phycoerythrin (PE) conjugated mAbs to IL-4 (3010.211),
CCR5 (2D7/CCR5), IL-5 (TRFK5), IL-13 (JES10±5A2), and integrin
b7 (FIB504), and PerCP- and allophycocyanin-coupled mAbs to CD4
(Leu-3a) were obtained from BD PharMingen (San Jose, CA). PE- and
RED670-conjugated streptavidins were from Gibco BRL (Gaithersburg,
MD). A recombinant Dermatophagoides farinae antigen Der f1, a
recombinant human interferon-g-inducible protein 10, and recombinant
human thymus and activation regulated chemokine and macrophage
in¯ammatory protein 1b were obtained from Asahi Beer Pharmaceutical
(Tokyo, Japan), R&D Systems (Minneapolis, MN), and PeproTech
(London, U.K.), respectively. Biotinylated rat anti-CRTH2 mAb BM16,
a puri®ed protein derivative of Mycobacterium tuberculosis (PPD), and
PGD2 used in this study were described previously (Nagata et al, 1999a;
Hirai et al, 2001).
Flow cytometric analysis To stain CRTH2 and other surface
molecules, cells were ®rst incubated in 0.5% bovine serum albumin/
0.05% NaN3/2 mM ethylenediamine tetraacetic acid/phosphate-buffered
saline (PBS) (washing buffer) containing 5% normal rat serum at room
temperature for 20 min to block nonspeci®c binding sites. Biotinylated
BM16 (®nal 10 mg per ml) and appropriate mAbs to surface markers
were then added to the cells and the mixture was incubated at room
temperature for 15±20 min. After washing with washing buffer, cells
were further incubated with PE- or RED670-conjugated streptavidin in
washing buffer at room temperature for 15 min. In the case of
intracellular cytokine staining, cells were ®xed in 4% formaldehyde/PBS
at room temperature for 5 min, permeabilized in Permeabilizing Solution
(BD PharMingen) at room temperature for 10 min, and stained with
mAbs to cytokines on ice for 45 min as described previously (Nagata et
al, 1999a). Stained cells were analyzed on a FACSCalibur ¯ow cytometer
(BD PharMingen) using CellQuest software (BD PharMingen).
Analysis of antigen-reactive Th cells by ¯ow cytometry Peripheral
blood mononuclear cells (PBMCs) were isolated from heparinized
peripheral blood using Ficoll Paque (Pharmacia Biotech, Uppsala,
Sweden). PBMCs were suspended in AIM-V medium (Gibco BRL) at
2±6 3 106 cells per ml, and the cell suspension (0.5 ml each) was
incubated with or without an antigen in Falcon 2063 round-bottomed
tube (BD PharMingen) at 37°C for 18±20 h. Brefeldin A (Wako Pure
Chemical, Osaka, Japan; ®nal 10 mg per ml) was added 60 min after
initiation of the culture. Cells were harvested and analyzed for their
expression of CD4, CRTH2, and cytokines by ¯ow cytometry as
described above.
Chemotaxis assay CD3+ PBMCs (> 95% pure) were isolated with
the MACS system (Miltenyi Biotec, Bergisch, Germany) and subjected
to chemotaxis assay using a 96-well microchemotaxis chamber with a
5 mm pore ®lter (NEURO PROBE, Gaithersburg, MD) as described
previously (Hirai et al, 2001). In brief, cells (1±5 3 105 cells per 50 ml
per well) and test compounds (29 ml per well) prepared in culture
medium (RPMI-1640 medium containing 10% fetal bovine serum and
10 mM HEPES, pH 7.3) were applied to top wells and bottom wells,
respectively, of the chamber. After incubation at 37°C for 60±90 min,
cells that migrated to the lower wells were carefully harvested and
stained with FITC-labeled anti-CD3, PerCP-labeled anti-CD4, and PE-
labeled BM16 (a kind gift of Immunotech, Marseille, France), and then
analyzed on a ¯ow cytometer in the presence of a ®xed number of
TruCount Beads (BD PharMingen). TruCount Beads were used to assess
the absolute number of cells per well.
Statistical analysis All data are expressed as mean 6 SEM. Differences
between groups were examined for statistical signi®cance using Student's
t test. A p-value less than 0.05 denoted the presence of a statistically
signi®cant difference.
RESULTS
Correlation between CRTH2 expression and Th2 phenotype
in circulating CD4+ lymphocytes In the ®rst step, we clari®ed
the mutual relationship between CRTH2 expression and Th2
phenotype in normal subjects and patients with AD. For this
purpose, we directly stimulated whole blood samples with phorbol
myristate acetate and ionomycin in the presence of brefeldin A in
order to fully stimulate leukocytes but avoid cell damage caused by
cell isolation procedures (Nagata et al, 1999a). The stimulated
leukocytes were then isolated and simultaneously examined for
CD4, CRTH2, and intracellular cytokines by four-color ¯ow
cytometry as shown in Fig 1(A). The proportions of IFN-g±IL-4+
cells, IFN-g±IL-13+ cells, IFN-g±(IL-4, IL-5, or IL-13)+ cells,
IFN-g+(IL-4, IL-5, or IL-13)+ cells, and IFN-g+(IL-4, IL-5, and
IL-13)± cells among CRTH2+CD4+ lymphocytes were 60.6 6
6.1%, 77.7 6 6.0%, 83.1 6 3.5%, 2.5 6 1.5%, and 1.2 6 1.2% in
normal adults (n = 9), and 54.6 6 8.8%, 86.1 6 5.2%, 88.3 6
4.6%, 0.7 6 0.4%, and 0.1 6 0.1% in AD patients (n = 7),
respectively (Fig 1B). Interestingly, within the CRTH2+CD4+
lymphocytes, acquisition of Th2 phenotype was more complete in
CRTH2highCD4+ lymphocytes than in CRTH2lowCD4+
lymphocytes for all subjects examined (Fig 1A and data not
shown). On the other hand, proportions of CRTH2+ cells among
IFN-g±IL-4+, IFN-g±IL-13+, IFN-g±(IL-4, IL-5, or IL-13)+, IFN-
g+(IL-4, IL-5, or IL-13)+, and IFN-g+(IL-4, IL-5, and IL-13)± Th
subsets were 54.1 6 4.1%, 52.1 6 6.7%, 43.7 6 5.6%, 3.8 6 3.0%,
and 0.2 6 0.1% in normal adults (n = 9) and 59.2 6 5.4%, 60.8 6
4.6%, 54.6 6 9.6%, 2.5 6 1.0%, and 0.2 6 0.1% in AD patients
(n = 7), respectively (Fig 1C). These results indicate that CRTH2
expression is frequently and selectively associated with Th2 cells
among circulating CD4+ lymphocytes in both normal and AD
subjects.
CRTH2 expression in allergen-responsive Th2 cells We
next addressed an intriguing question of whether CRTH2 is
actually associated with circulating Th2 cells that are reactive to
disease-related natural antigens. To this end, PBMCs from subjects
with high IgE titer for mite allergens were stimulated in vitro with a
typical mite allergen Der f1 or a typical Th1-related antigen PPD,
and the expression levels of CRTH2 and cytokines were examined
by ¯ow cytometry. As shown in Fig 2(A), the majority of Th2
cytokine-producing CD4+ lymphocytes in Der f1-stimulated
cultures were positive for CRTH2. In contrast, PPD-responsive
Th1 cytokine-producing CD4+ lymphocytes were completely
negative for CRTH2. Similar results were obtained in three healthy
and two AD subjects (Fig 2B).
Responsiveness of CRTH2+ Th cells to PGD2 and
chemokines To further characterize circulating CRTH2+ Th
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cells we next investigated their chemotactic responses to PGD2 and
chemokines. As shown in Fig 3, CRTH2+, but not CRTH2±, Th
cells from healthy subjects were signi®cantly attracted by PGD2 at
nanomolar concentrations. CRTH2+ Th cells were attracted more
effectively by a typical Th2-attracting chemokine, thymus and
activation regulated chemokine (CCR4 agonist) (Bonecchi et al,
1998; Imai et al, 1999). In contrast, they exhibited no signi®cant
migration toward a typical Th1-attracting chemokine, macrophage
in¯ammatory protein 1b (CCR5 agonist) (Bonecchi et al, 1998;
Loetscher et al, 1998) at concentrations up to 100 nM.
Furthermore, the effect of another Th1-related chemokine,
interferon-g-inducible protein 10, a CXCR3 agonist (Bonecchi
et al, 1998), was noted only at high concentrations. These results are
consistent with our previous observations that CRTH2+ Th cells of
healthy subjects expressed high levels of CCR4 but low or
negligible levels of CCR5 and CXCR3 (Cosmi et al, 2000).
Expansion of CRTH2+CD4+ lymphocytes in patients with
AD The above ®ndings suggested that most circulating
CRTH2+ Th cells may behave in vivo as typical Th2 cells with
respect to the cytokine pro®le they produce, the nature of the
antigens they respond to, and responsiveness to chemokines.
Therefore, we next addressed an interesting issue of whether
CRTH2 together with CLA and Th1-related surface molecules can
be used to assess the Th1/Th2 balance in AD. To this end,
peripheral blood leukocytes from a large panel of subjects (24
normal and 40 AD subjects) were simultaneously stained for CD4,
CRTH2, CCR5, and CLA, and the stained cells were analyzed as
described below. In parallel, proportions of Th1 and Th2 cells in
the same blood samples were determined based on the staining for
surface CD4 and intracellular cytokines after treatment with
phorbol myristate acetate, ionomycin, and brefeldin A for 4±5 h.
We ®rst analyzed for expression levels of CLA on
CRTH2+CD4+ lymphocytes. As shown in Fig 4, the frequency
of CLA+CRTH2+ cells was signi®cantly increased among CD4+
lymphocytes in AD patients compared with normal subjects. In
contrast, there was no signi®cant increase in the number of
CLA±CRTH2+ cells in AD patients. In the same AD patients, the
frequency of CRTH2+ Th cells coexpressing b7 integrin, a gut-
related homing receptor (Butcher and Picker, 1996), was not
changed whereas the frequency of b7-integrin-negative CRTH2+
Th cells was slightly increased (Fig 4B). It thus appeared that
CRTH2+ Th cells expressing CLA but not b7 integrin were
preferentially increased in AD patients, suggesting that enhanced
Th2 responses took place mainly in the skin in the AD patients
examined.
We next analyzed for the relationship between expression levels
of CRTH2 and CCR5 in Th cells. As shown in Fig 5, in normal
subjects, expression levels of CRTH2 and CCR5 were mutually
exclusive for most CD4+ lymphocytes, although a few
CRTH2+CD4+ lymphocytes weakly expressing CCR5 were also
observed. Unexpectedly, such CRTH2+CCR5+ cells were more
frequently observed among total CD4+ and CLA+CD4+ lympho-
Figure 1. Correlation between CRTH2 expression and Th2
phenotype in CD4+ lymphocytes. Heparinized peripheral blood from
nine normal and seven AD subjects were treated with phorbol myristate
acetate (20 ng per ml), ionomycin (1 mg per ml), and brefeldin A (10 mg
per ml) for 4±5 h, and the leukocytes were puri®ed with erythrocyte-
lysing solution. The cells were then stained for CD4 (allophycocyan) and
CRTH2 (RED670), ®xed, permeabilized, and additionally stained with
mAbs to IFN-g (FITC) and Th2 cytokines (PE; IL-4, IL-13, or a
mixture of mAbs to IL-4, IL-5, and IL-13) as described in Materials and
Methods. In (A), expression pro®les for CD4, CRTH2, and intracellular
cytokines of leukocytes from a patient with moderate AD in four-color
¯ow cytometry are shown. Panel a, whole leukocytes; panels b and c,
CRTH2 expression and cytokine pro®le in total CD4+ lymphocytes
gated as shown in panel a. Panels R1, R2, R3, and R1 + R2 + R3,
cytokine pro®les of the cells gated as shown in panel b. Panels R4±R7,
CRTH2 expression on the cells gated as shown in panel c. Quadrants
were set according to the staining of control mAbs. Percentages of cells
are given in each quadrant. In (B), proportions (%) of each Th subset
among total CRTH2+CD4+ lymphocytes are shown. In (C), proportions
(%) of CRTH2+ cells among each Th subset are presented. In (B) and
(C), data are mean 6 SEM. *p < 0.05, **p < 0.01, compared with the
IFN-g±IL-4+ subset of normal adults.
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cytes in AD patients than in normal adults (Fig 5). Frequencies of
both CRTH2+CCR5± and CRTH2+CCR5+ cell populations
among CLA±CD4+ lymphocytes were not signi®cantly different
between normal and AD subjects (data not shown). As indicated in
Fig 1, CRTH2-expressing CD4+ lymphocytes, including the
CRTH2+CCR5+ cells, were considered as mostly Th2, but not
Th1, cells. Therefore, we used a phenotype ``CRTH2±CCR5+'' as
a tentative marker for Th1 cells in the following analysis.
In the total 64 subjects, the proportion of total CRTH2+
(CRTH2+CCR5± plus CRTH2+CCR5+) cells among CD4+
lymphocytes correlated signi®cantly with that of Th2 cells (IFN-
g±IL-4+, r = 0.88: IFN-g±IL-13+, r = 0.92), but not Th1 cells (IFN-
g+IL-4±, r = 0.16) (Fig 6A). Furthermore, the proportions of Th2
cells and CRTH2+ cells among CD4+ lymphocytes in AD patients
increased proportionately with the progression of the disease
(Fig 6B). On the other hand, the frequency of CRTH2±CCR5+
cells among CD4+ lymphocytes roughly correlated with that of
Th1 cells (r = 0.77), but not Th2 cells (IFN-g±IL-4+, r = 0.07;
IFN-g±IL-13+, r = 0.03) (Fig 6A), also, CRTH2±CCR5+ cells
decreased with the progression of AD as well as Th1 cells (Fig 6B).
We further analyzed in detail for frequencies of CRTH2+,
CRTH2±CCR5+, and remaining CRTH2±CCR5± Th cells in
relation to CLA (Fig 6C). The frequency of CLA+CRTH2+ cells
among total CD4+ lymphocytes was increased in patients with
moderate and severe AD whereas those of CLA+CRTH2±CCR5+
and CLA+CRTH2±CCR5± cells, as well as the frequency of total
CLA+ cells, were increased only in patients with severe AD. The
correlation between disease severity and expansion of CRTH2+
cells in AD patients was most clearly illustrated when CLA+CD4+
lymphocytes were examined (Fig 6C, upper right panel). In sharp
contrast, among CLA±CD4+ lymphocytes, there was no signi®cant
difference in the frequency of CRTH2+ cells between each group.
As reported for Th1-type cells (Akdis et al, 1997; Nakazawa et al,
1997; Teraki et al, 2000), CRTH2±CCR5+ cells were signi®cantly
decreased among both the CLA±CD4+ and the CLA+CD4+
lymphocyte populations in AD patients with the progression of the
disease. In the same AD patients, however, the proportion of total
CCR5+ cells among CLA+CD4+ lymphocytes was not signi®-
cantly decreased because of an increase of the CRTH2+CCR5+
cells (data not shown). The frequency of CRTH2±CCR5± cells
was decreased among CLA+CD4+ lymphocytes and increased
among CLA±CD4+ lymphocytes with the progression of the
disease (Fig 6C).
DISCUSSION
PGD2, a proin¯ammatory lipid mediator (Flower et al, 1976), is the
major prostanoid that is produced by activated mast cells and
therefore has long been implicated in allergic diseases (Lewis et al,
1982; Giles and Leff, 1988; Narumiya et al, 1999). Recent studies
Figure 2. CRTH2 expression in antigen-responsive CD4+
lymphocytes. PBMCs were stimulated with PBS (unstimulated), Der f1
(3 mg per ml), or PPD (10 mg per ml) for 18±20 h and then examined
for the expression levels of CRTH2 (RED670) and cytokines (PE)
among CD4+ lymphocytes. In (A), results for CD4+ lymphocytes from
two donors are shown. Percentages of cells are given in each quadrant.
In (B), data for ®ve donors are summarized. Net percentages of cells
(percentage in cytokine staining minus percentage in control staining) are
plotted (*p < 0.05, **p < 0.01).
Figure 3. Chemotactic responses of CRTH2+ Th cells to PGD2
and chemokines. CD3+ PBMCs (4 3 105 cells per well) isolated from
a healthy adult were examined for their chemotactic responses to PGD2
and indicated chemokines (nM, n = 4) for 70 min as described in
Materials and Methods. The numbers of CRTH2±CD3+CD4+ cells (A)
and CRTH2+CD3+CD4+ cells (B) per lower well are shown. Data are
mean 6 SEM. *p < 0.05, **p < 0.01, compared with the control group
(medium alone). Note that concentrations of PGD2 were set differently
from those of chemokines because its effective range of concentrations
was relatively narrow. Similar results were obtained in three other
normal adults.
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from our laboratories elucidated that PGD2 utilizes two structurally
distinct G protein-coupled receptors, DP receptor (DP) (Boie et al,
1995) and CRTH2, as its speci®c receptors (Hirai et al, 2001). In
response to PGD2, DP induces Ca
2+ in¯ux and cAMP generation
through Gas-type G protein, which lead to vasodilation, relaxation
of smooth muscles, and inhibition of dendritic cell migration (Giles
and Leff, 1988; Narumiya et al, 1999; Angeli et al, 2001). In
contrast, CRTH2 is coupled with Gai-type G protein and induces
cell migration in eosinophils, basophils, and Th2 lines (Hirai et al,
2001), which strongly suggests the involvement of CRTH2 in
allergic in¯ammation. Interestingly, DP has been shown recently to
be involved in some steps in the formation of allergic in¯ammation
by studies with DP-de®cient mice (Matsuoka et al, 2000). On the
other hand, PGD2 has been demonstrated to have anti-in¯amma-
tory properties in some in¯ammation models, probably via DP
(Gilroy et al, 1999; Ajuebor et al, 2000). Thus, the exact roles of
PGD2 in various in¯ammatory responses are just beginning to be
explored.
We previously reported that CRTH2-expressing CD4+ lym-
phocytes were increased in the peripheral blood of patients with
severe AD (Cosmi et al, 2000). Our study con®rmed this and
clari®ed further aspects of circulating CRTH2+ Th cells. Our study
demonstrated ®rst that practically all CRTH2+ Th cells from both
normal and AD subjects possessed the pure Th2 phenotype. The
®nding that acquisition of Th2 phenotype was more complete in
CRTH2highCD4+ lymphocytes than in CRTH2lowCD4+
Figure 4. Expression levels of CRTH2 and homing receptors on
CD4+ lymphocytes from normal and AD subjects. Whole
leukocytes were puri®ed from heparinized peripheral blood from 24
normal and 40 AD subjects with erythrocyte-lysing solution and were
stained for CD4 (allophycocyan), CRTH2 (RED670), CCR5 (PE), and
CLA (FITC). Some of the same leukocyte samples were also stained for
CD4, CRTH2, and integrin b7 (PE). (A) Representative expression
patterns of CRTH2, CLA, and integrin b7 in CD4+ lymphocytes from
two healthy and two AD subjects are shown. Percentages of cells are
given in each quadrant. (B) The frequency of CLA±CRTH2+ and
CLA+CRTH2+ cells (normal, n = 24; AD, n = 40) and that of integrin
b7 (b7±CRTH2+ and b7+CRTH2+ cells) (normal, n = 11; AD, n = 26)
among CD4+ lymphocytes are presented. Data are mean 6 SEM.
**p < 0.01.
Figure 5. Expansion levels of CRTH2 and CCR5 on CD4+
lymphocytes from normal and AD subjects. The same stained
leukocyte samples as described in Fig 4 were analyzed for expression
levels of CD4 (allophycocyan), CLA (FITC), CRTH2 (RED670), and
CCR5 (PE). (A) Representative staining patterns for CRTH2 and
CCR5 among total CD4+, CLA+CD4+ (R1), and CLA±CD4+ (R2)
lymphocytes are shown. Percentages of cells are given in each quadrant.
(B) Frequencies of CRTH2+CCR5±, CRTH2+CCR5+, and
CRTH2±CCR5+ cells among total CD4+ and CLA+CD4+ lymphocytes
are shown (normal, n = 24; AD, n = 40). Data are mean 6 SEM.
**p < 0.01.
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lymphocytes supports a close relationship between CRTH2
expression and Th2 phenotype. Our study also revealed that
CRTH2 was not necessarily expressed in all circulating Th2 cells
but was associated with about half of them at least in the normal and
AD subjects examined. These results suggest that the number of
circulating CRTH2+ Th cells may re¯ect that of circulating Th2
cells even though the two are not of equal value. Indeed, in a large
panel of subjects (n = 64), the proportion of CRTH2+ cells among
CD4+ lymphocytes correlated signi®cantly with that of Th2 cells
for both normal and AD subjects. Consistently, the proportions of
CRTH2+ cells and Th2 cells among CD4+ lymphocytes increased
proportionately with the progression of AD. On the other hand,
our results also demonstrated that circulating allergen-responsive
Th2 cells were mostly positive for CRTH2. Combined together,
these results suggest that CRTH2 represents a large subpopulation
of circulating Th2 cells that includes such Th2 cells that are highly
susceptible to disease-related antigens. Our ®nding that the
expansion of CRTH2+ Th cells in AD patients was preferentially
seen within the CLA+ Th cell population may support this concept
because it was reported that allergen-responsive T cells of AD
patients were largely con®ned to the CLA+ subset (Santamaria Babi
et al, 1995).
Recently, an increased proportion of CRTH2+CD4+ lympho-
cytes has also been demonstrated in other Th2-enhancing condi-
tions such as advanced HIV infection and pregnancy (Cosmi et al,
2000; Tsuda et al, 2001). Therefore, selective association of
CRTH2 with Th2 cells might generally hold in vivo in various
physiologic and pathophysiologic conditions. Studies in other
disease settings including Th1-dominated diseases are required to
establish the intriguing link between CRTH2 and Th2 phenotype.
Previous studies have shown that CLA-bearing Th2-type cells
were signi®cantly increased in peripheral blood of AD patients
(Akdis et al, 1997; Teraki et al, 2000). Our study con®rmed this by
exploiting CRTH2 as a Th2-selective surface molecule. These
®ndings are somehow interesting in view of the regulation
mechanisms of CLA in Th cells. Previous in vitro studies
demonstrated that CLA expression is mainly induced by a strong
Th1-inducing cytokine IL-12 (Leung et al, 1995; Teraki and
Picker, 1997). Indeed, enhanced IL-12 expression was demon-
strated in chronic AD skin lesions (Hamid et al, 1996). Therefore,
Figure 6. Expansion of CRTH2+ cells among the CLA+CD4+ lymphocyte compartment in AD patients. With the same stained leukocyte
samples as described in Fig 4 various analyses were made. (A)Correlation of frequencies of CRTH2+ cells (upper panels) and CRTH2±CCR5+ cells
(lower panels) to those of IFN-g+IL-4±, IFN-g±IL-4+, and IFN-g±IL-13+ cells among total CD4+ lymphocytes in healthy (n = 24) and AD (n = 40)
subjects. (B), (C)Comparison of frequencies (%) of each cell subset among total CD4+ (B, C), CLA±CD4+, and CLA+CD4+ lymphocyte populations
(C) in normal subjects (N, n = 24) and patients with mild (mi, n = 5), moderate (mo, n = 18), and severe (se, n = 17) AD. The mean value of each
group is indicated by a bold horizontal bar. *p < 0.05. **p < 0.01.
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locally produced IL-12 might contribute to the enhanced CLA
expression on the CRTH2+ Th cells of AD patients. Our
observation that CCR5 expression was preferentially increased
among CLA+, but not CLA±, CRTH2+ Th cells in AD patients
supports this idea because CCR5 is also upregulated by IL-12
(Rogge et al, 2000). In general, IL-12 induces Th1 phenotype as
well as CLA expression in most cultured Th cells (Abbas et al, 1996;
Teraki and Picker, 1997; Akdis et al, 2000). Furthermore, IL-12
plus T cell activation signals induced signi®cant downregulation of
CRTH2 in Th2 cells (Annunziato et al, 2001). Teraki and Picker
(1997), however, showed that CLA expression was much more
rapidly reversible than cytokine synthesis capability in established
Th cells. In addition, IL-12 treatment alone had a limited inhibitory
effect on the CRTH2 expression of established Th2 clones (Nagata
et al, 1999a). Thus, it is conceivable that in certain situations
CRTH2+ Th2 cells can concomitantly express CLA in response to
IL-12. Recently, Akdis et al (2000) reported that in some culture
conditions T cell activation alone was suf®cient to induce CLA in
Th2 lines. This ®nding suggests yet unknown IL-12-independent
CLA-inducing mechanisms. Comparative analysis between CLA-
positive and CLA-negative CRTH2+ Th cells in vivo may provide
some insights into this issue.
The signi®cance of PGD2 in the development of AD still
remains unclear at present. Ruzicka et al reported that PGD2
concentration in suction blister ¯uids from lesional AD skin was
under the detection limit (360 pg per ml; Ruzicka et al, 1986).
Charlesworth et al (1993), however, observed an elevation of PGD2
levels during the 3 h after allergen challenge using the blister
chamber method with AD patients. Signi®cant production of
PGD2 in allergen-challenged skin was also observed in patients
with other allergic diseases such as asthma and hay fever as well as in
atopic subjects (Barr et al, 1988; Pienkowski et al, 1988). We
demonstrated in this study that PGD2 could selectively attract
peripheral-blood-derived CRTH2+ Th cells at nanomolar con-
centrations. Therefore, it is conceivable that PGD2 produced at the
sites of allergen challenge in the skin may recruit circulating
CRTH2+ Th cells. Although we could not directly investigate
accumulation of CRTH2+ Th cells into the lesional skin of AD,
our ®nding of a preferential increase of CRTH2+ Th cells within
the skin-homing CLA+ Th cell population appears to support such
an idea. In the lesional skin of AD, however, enhanced expression
of other Th2-attracting chemoattractants, such as chemokines
eotaxin and thymus and activation regulated chemokine, was
observed (Yawalkar et al, 1999; Vestergaard et al, 2000). The
relative importance of the PGD2/CRTH2 system in the prefer-
ential accumulation of Th2 cells into the sites of allergic
in¯ammation should be elucidated by using speci®c antagonists
or CRTH2-de®cient animals.
Finally, our study also showed the possible use of CRTH2
combined with CLA and Th1-related surface molecules to predict
the balance between Th1 and Th2 cells in AD. Many studies have
shown that CCR5 is preferentially associated with Th1 cells in vitro
(Bonecchi et al, 1998; Loetscher et al, 1998; Sallusto et al, 1998a)
and in vivo (Qin et al, 1998; Balashov et al, 1999). Our results
demonstrated that CCR5 was expressed even in some of the
circulating CRTH2+ Th2 cells in normal adults and, more
frequently, in AD patients. This ®nding is not surprising because
CCR5 has been reported to be expressed at various levels even in
Th2 clones (Sallusto et al, 1998a). The enhanced expression of
CCR5 on CRTH2+ Th2 cells of AD patients might re¯ect an
increased expression of Th1-related cytokines such as IL-12 and
IFN-g at chronic lesions of AD (Hamid et al, 1996; Grewe et al,
1998) because CCR5 is known to be upregulated by such
cytokines (Syrbe et al, 1999; Rogge et al, 2000). These results
imply that, at least in the case of AD, CCR5 cannot be simply used
as a marker for Th1 cells. Our results showed that
CRTH2±CCR5+ Th cells were better correlated with circulating
Th1 cells than simple CCR5+ Th cells, especially among the skin-
homing CLA+ Th cell compartment of AD patients. The usefulness
of such an approach must be con®rmed in further studies.
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